Thd that proved highly cytostatic for murine leukaemia L1210 cells. The decreased biological activity of the N-3-substituted pyrimidine nucleoside analogues coincides with a significantly lower affinity of the modified Thd analogues for the cellular and viral (activating) nucleoside kinases.
3′-Fluoro-3′-deoxythymidine (FLT) is a thymidine (Thd) analogue that is endowed with potent and selective antiretroviral activity (Herdewijn et al., 1987) . Among the nucleoside reverse transcriptase inhibitors, FLT is one of the most potent antiviral drugs in cell culture. It inhibits HIV replication at very low concentrations [50% effective concentration (EC 50 ): 0.0003 µg/ml in MT-4 and 0.002 µg/ml in CEM cell cultures (Balzarini et al., 1988; MT-4) and unpublished (CEM)]. However, it also has a pronounced cytostatic activity in cell culture. Nevertheless, FLT (designated MIV-310) is currently the subject of clinical studies on salvage therapy of drug-experienced HIVinfected individuals (Katlama et al., 2004) and has also been shown to suppress multidrug-resistant virus mutants (Kim et al., 2001) . 1-β-D-arabinosylthymine (ara-T) represents another Thd analogue that shows activity against herpes virus in cell culture (Gentry & Aswell, 1975; Miller et al., 1977; Allen et al., 1987) . In contrast with FLT, which needs to be activated (phosphorylated) by cellular (cytosolic) thymidine kinase (TK-1) to exert its antiretroviral activity (Balzarini et al., 1988) , ara-T is activated by herpes simplex virus (HSV)-encoded TK to exert its antiviral activity (Dahmen et al., 1990) . Interestingly, a range of anti-HSV compounds, including ara-T, gain marked cytostatic activity against tumour cells that are transduced with the TK gene of HSV in cell culture (Balzarini et al., 1985; Rubsam et al., 1998) . Therefore, anti-herpes agents, in particular ganciclovir, have been considered as potential anti-tumour agents in a combined gene/chemotherapy approach (Balzarini et al., 1985 (Balzarini et al., , 1994 Moolten, 1986; Culver et al., 1992) .
Several sites on the Thd molecule have been extensively explored to synthesize new analogues with the aim to improve the antiviral or cytostatic activity (for example, the C-5 position in the thymine base). However, the N-3 position in the thymine base has never been explored in full detail. Recently, Thd modified at N-3 with a methyl, ethyl, propynyl, n-butyl, benzyl or 2,3-dihydroxypropyl group has been synthesized and found to keep marked substrate activity for cytosolic TK-1 with the phosphorylation rate ranging between 27% and 102% of that of unsubstituted Thd (Bandyopadhyaya et al., 2005) . The synthesis of N-3-(methyl)-Thd and N-3-(methyl)-ara-T have also been reported by Shimizu et al. (2005) and Saffhill (1987) . A variety of 3-(carboranylalkyl) Thd derivatives have been synthesized where an alkyl spacer of 2-7 methylene units was inserted between the 0-carborane cage and the Thd scaffold. These compounds keep good substrate activity for TK-1 but not for mitochondrial TK-2 (Al-Madhoun et al., 2002 . At first glance, the retained affinity for TK-1 is surprising, as the recently resolved crystal structure of TK-1 revealed that O-2, N-3 and O-4 of the thymine base form hydrogen bonds to main chain atoms of the enzyme (Welin et al., 2004) . However, the N-3 position of the ring seems to point towards a rather flexible domain in TK-1, and it is believed that the substituents at N-3 may compensate the loss of a hydrogen bond to N-3 by other interactions with the enzyme (Welin et al., 2004) . Thus, these observations revealed that bulky groups at N-3 of the thymine ring may be allowed without markedly compromising its interaction with cytosolic TK1. Therefore, we aimed to synthesize the N-3-(methyl) and N-3-(2-fluoroethyl) derivatives of FLT and ara-T ( Figure 1 ), and also attached these substituents to Thd for comparative purpose. A 2-fluoroethyl substituent was also used because a 18 F-labelled form could serve as a potential tracer for the in vivo visualization of tumour cell proliferation with positron emission tomography, if sufficient substrate affinity for cytosolic TK-1 could be preserved in the molecule. The novel nucleoside derivatives were evaluated for their inhibitory activity against a broad range of DNA and RNA viruses, their substrate activity for recombinant viral and cellular nucleoside kinases, and their cytostatic activity against several tumour cell lines.
Materials and methods

Chemistry
All reagents were obtained commercially from Acros (Geel, Belgium), Fluka (Bornem, Belgium) or Merck (Darmstadt, Germany). 1 H and 13 C-NMR spectra were recorded on a Gemini 200 MHz spectrometer (Varian, Palo Alto, CA, USA). Chemical shifts are reported in parts per million relative to tetramethylsilane (TMS; δ=0). Coupling constants (J) are reported in Hertz. Splitting patterns are defined by s (singlet), d (doublet), dd (double doublet), t (triplet), dt (double triplet), q (quartet) and m (multiplet). HPLC analysis was performed on an XTerra RP18 column (5 µm, 4.6 mm × 250 mm; Waters, Milford, USA), and a carbohydrate amino column (10 µm, 4.1 mm×300 mm; Alltech, Deerfield, IL) eluted with gradient mixtures of water and acetonitrile. The column effluent was monitored with an UV-detector set at 270 nm and the output signal was analysed using a RaChel analysis program (Lablogic, Sheffield, UK). The purity of the compounds was determined with HPLC-UV detection and was found to be >97%. Exact mass measurements were performed on a time-of-flight spectrometer (LCT, Micromass, Manchester, UK) equipped with a standard electrospray ionization (ESI) interface. Samples were infused in acetonitrile/water with a Harvard 22 syringe pump (Harvard instruments, Holliston, MD, USA). Accurate mass determination was done by co-injection of a Thd solution as an internal calibration mass. Acquisition and processing of the data was done with Masslynx software (Micromass, Manchester, UK).
Melting points (mp) were determined with an Electrothermal IA9000 digital melting point apparatus (Electrothermal, Southend-on-Sea, England).
N-3-(methyl)-Thd. (Shimizu et al., 2005) . To a solution of 0.79 g (3.3 mmol) Thd in 50 ml methanol were added 0.83 g (6 mmol) anhydrous K 2 CO 3 and dropwise 0.19 ml (3.8 mmol) methyl iodide. Stirring was continued for 1 day at 37°C. The reaction mixture was neutralized with a 1 M solution of acetic acid in methanol. An amount of 3g silica gel was added and the solvent was evaporated. The residue was stripped with 10 ml CH 2 Cl 2 . The silica gel impregnated with the crude product was applied on a silica gel column that was eluted with a gradient of ethyl acetate/hexane (8:2 v/v increased to 9:1 v/v), yielding 0. N-3-(methyl)-ara-T. The same procedure was used as described for N-3-(methyl)-Thd, but starting from ara-T (0.1 g, 0.38 mmol) instead of Thd (Saffhill, 1987 (Balzarini et al., 1988; De Clercq et al., 1986 , 1987 .
Cytostatic assays. The cytostatic activity assays were performed in 96-well microtitre plates. Around 5×10 4 cells suspended in RPMI-1640 cell culture medium were allowed to proliferate in 200 µl wells in the presence of a fivefold dilution of the test compounds at 37°C in a humidified CO 2 -controlled atmosphere. After 48 h (L1210 and FM3A) or 72h (CEM), the number of living cells was counted in a Coulter counter (Harpenden, Herts, UK). The IC 50 was defined as the compound concentration required to inhibit tumour cell proliferation by 50%.
Inhibition of nucleoside kinase-catalysed Thd phosphorylation by the test compounds.
The radiolabelled substrate [methyl-3 H]dThd (70 Ci/mmol) was obtained from Amersham Pharmacia Biotech (Buckinghamshire, UK). The cDNAs of TK-1, TK-2, HSV-1 TK and VZV TK were inserted in the pGEX-5X-1 vector, expressed as fusion proteins to glutathione S-transferase, and purified as described (Johansson & Karlsson, 1997; Sienaert et al., 2002) . The activity of the purified recombinant nucleoside kinases were assayed in a 50 µl reaction mixture containing 50 mM Tris-HCl, pH 8.0, 2.5 mM MgCl 2 , 10 mM dithiothreitol, 0.5 mM CHAPS, 3 mg/ml bovine serum albumin, 2.5 mM ATP, [methyl-3H]dThd (1 µM final concentration; specific radioactivity: 48 Ci/mmole) and recombinant enzyme. The samples were incubated at 37°C for 30 min in the presence or absence of different concentrations of the test compounds. Aliquots of 45 µl of the reaction mixtures were spotted on Whatman DE-81 filter paper disks (Whatman Int., Maidstone, UK). The filters were washed three times for 5 min in 1mM ammonium formate and once for 5 min in ethanol. The radioactivity was determined by scintillation counting.
Results
The intended products, that is, N-3-(methyl)-Thd, N-3-(methyl)-FLT and N-3-(methyl)-ara-T were each respectively synthesized in a one-step reaction of Thd, FLT and ara-T with methyl iodide as alkylating agent in methanol at 37°C. K 2 CO 3 was added as a base. The N-3-(2-fluoroethyl) analogues were synthesized using the same procedure, but with 2-fluoroethyl tosylate as alkylating agent at 75°C (Figure 2) . While alkylation at other positions of these Thd derivatives may generally be possible under these reaction conditions, it has not been reported in literature (Lunato et al., 1999) 100-400 µg/ml except for N-3-(2-fluoroethyl)-FLT that was active against HIV-1 and HIV-2 at an EC 50 of 50 ±42 and 90 ±14 µg/ml, respectively. However, this antiviral activity was still four orders of magnitude less than the parent compound FLT (EC 50 : 0.002 µg/ml). Also the compounds were not cytotoxic to HEL, HeLa nor Vero cell cultures at 400 µg/ml, and not cytostatic against proliferating CEM cell cultures at 250 µg/ml. Whereas none of the compounds was cytostatic against murine mammary carcinoma FM3A cells at 500 µg/ml, N-3-(methyl)-Thd proved exquisitely inhibitory to murine leukaemia L1210 cell proliferation (IC 50 :0.74 µg/ml; Table 1 ). N-3-(2-fluoroethyl)-Thd was markedly less inhibitory to L1210 cells (IC 50 :119 µg/ml), whereas the modified FLT and ara-T derivatives lacked any appreciable inhibitory effect against L1210 tumour cell proliferation at 500 µg/ml In order to explain the virtual lack of antiviral and cytostatic activity of the N-3-substituted FLT and ara-T derivatives, the affinity of the test compounds was determined for purified cytosolic TK-1 and recombinant mitochondrial TK-2, HSV-1 TK and VZV TK (Table 2) . Whereas FLT showed a pronounced affinity for TK-1, and in particular for TK-2 and HSV-1 TK (IC 50 :1.1-6.7 µg/ml) and a modest affinity for VZV TK (IC 50 :56 µg/ml), introduction of a methyl or a 2-fluoroethyl entity at N-3 of FLT markedly decreased the affinity of the test compounds for the nucleoside kinases (IC 50 :197 and 215 µg/ml for HSV-1 TK, respectively, and an IC 50 >500 µg/ml for TK-1, TK-2 and VZV TK). Also, whereas ara-T had pronounced affinity for HSV-1 and VZV TK (IC 50 :5.2-6.0 µg/ml), the modifications at N-3 in ara-T resulted in a substantial loss of significant affinity for these activating enzymes (IC 50 : >500 µg/ml). Interestingly, N-3-(methyl)-Thd and also N-3-(2-fluoroethyl)-Thd retained the best affinity among the modified nucleoside analogues for TK-1 (77-81 µg/ml), TK-2 (81-241µg/ml), HSV-1 TK (52-56 µg/ml) and VZV TK (94-450 µg/ml).
Discussion
A series of N-3-substituted Thd, FLT and ara-T derivatives have been synthesized and evaluated for their potential inhibitory effect against a range of viruses, and also for their cytostatic activity against murine and human tumour cell lines. In contrast with the parent compounds FLT and ara-T, none of the N-3-substituted nucleoside analogues showed measurable antiviral activity. To explain these observations, the test compounds were evaluated for their affinity for several nucleoside kinases that can metabolically activate the compounds. Although measurable affinity of some of the N-3-substituted Thd and FLT analogues was found for TK-1, TK-2, HSV-1 TK and/or VZV TK, the observed affinities of the N-3substituted Thd analogues for the cellular and viral TKs proved not sufficient to provide antiviral or cytostatic activity in cell culture for these compounds. Evidently, despite the affinity for their phosphorylating (activating) nucleoside kinases, the lack of antiviral and cytostatic activity of the N-3-(methyl)-and N-3-(2-fluoroethyl)substituted Thd derivatives also points to a poor, if any, inhibitory activity of the phosphorylated metabolites of the Thd analogues for their antiviral and cytostatic target enzymes (that is, viral and cellular DNA polymerases). Alternatively, the compounds may not be efficiently further metabolized to their 5′-triphosphate derivatives by the cellular nucleotide kinases. Affinity studies of the 5′triphosphate derivatives with the viral and cellular DNA polymerases would reveal the reason for the virtual inactivity of the N-3-substituted nucleoside analogues. The exquisite selective cytostatic activity of N-3-(methyl)-Thd against murine leukaemia L1210, but not murine mammary carcinoma FM3A and human lymphocyte CEM cells is surprising. However in a previous study by Balzarini et al. (1983) , L1210 cells have been shown to be very sensitive to the cytostatic activity of natural Thd with an IC 50 of 12 µg/ml (in this study: 4 µg/ml). This unusual strong inhibitory activity on L1210 cell proliferation has been interpreted as being due to a high sensitivity of ribonucleotide reductase to the allosteric inhibition by thymidine-5′-triphosphate (TTP). Evidently, this enzyme must most likely be even more sensitive to the inhibitory effect of N-3-(methyl)-TTP [but not N-3-(2-fluoroethyl)-TTP]. The markedly decreased cytostatic activity of N-3-(methyl)-Thd against L1210/TKcells that are deficient for cytosolic TK-1 (data not shown) indeed points to a phosphorylated metabolite of N-3-(methyl)-Thd being responsible for its cytostatic activity, and is not in disagreement with the hypothesis that ribonucleotide reductase is a target for inhibition by the phosphorylated metabolite of N-3-(methyl)-Thd.
In conclusion, our observations strongly suggest that N-3-substituted FLT and ara-T derivatives markedly loose affinity for the activating (phosphorylating) nucleoside kinases resulting in a decrease or even annihilation of their biological activity. However, it is currently unclear whether efficient phosphorylation of the modified Thd, FLT and ara-T analogues to their 5'-triphosphates and/or lack of marked affinity of the nucleoside 5'-triphosphate derivatives for their target enzymes, viral and cellular DNA polymerases, is the reason of the virtual lack of biological activity of the test compounds. ©2006 International Medical Press Table 2 . Inhibitory activity of N-3-substituted Thd, FLT and ara-T analogues on the phosphorylation of 1 µM [3H]Thd by purified recombinant nucleoside kinases Compound IC 50 (µg/ml) TK-1 TK-2 HSV-1 VZV TK N-3-(methyl)-Thd 77 ±1 241 ±3 5 6 ±1 450 N-3-(2-fluoroethyl)-Thd 81 81 ±9 5 2 ±5 9 4 N-3-(methyl)-FLT >500 >500 197 ±32 >500 N-3-(2-fluoroethyl)-FLT >500 >500 215 ±13 >500 N-3-(methyl)-ara-T >500 >500 >500 >500 N-3-(2-fluoroethyl)-ara-T >500 >500 >500 >500 FLT 6.7 ±0.25 1.2 ±0.0 1.1 ±0.025 56 ±19 Ara-T >125 71 ±23 6.0 ±0.75 5.2 ±1.5
Ara-T, 1-β-D-arabinosylthymine; FLT, 3′-Fluoro-3′-deoxythymidine; HSV, herpes simplex virus; IC 50 , 50% Inhibitory concentration, or compound concentration required to inhibit cell proliferation by 50%; Thd, thymidine; TK, thymidine kinase; VZV, varicella-zoster virus.
